Theranostic proteomic profiling of cyclins, cyclin dependent kinases and Ras in human cancer cell lines is dependent on p53 mutational status

International Journal of Oncology

Volumn 32, Issue 4, 2008, Pages 895-907

  Warenius, Hilmar M ^a,b   Seabra, Laurence ^a   Kyritsi, Lito ^a   White, Ros ^a   Dormer, Roisin ^a   Anandappa, Shanez ^a   Thomas, Carole ^a   Howarth, Amanda ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Theryte Ltd   (United Kingdom)

Author keywords

Cdks; Clonogenic cell survival; Cyclins; P53 mutational status; Proteomic; Ras; Theranostic

Indexed keywords

CISPLATIN; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 4; CYCLINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; INTERCALATING AGENT; PACLITAXEL; PLATINUM COMPLEX; PROTEIN P53; RAS PROTEIN; TAXANE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL AGING; CELL DIVISION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; GENE CONTROL; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDICAL RESEARCH; MOLECULAR BIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; WILD TYPE; CHEMISTRY; GENETICS; MUTATION; NEOPLASM; STATISTICAL MODEL; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASES; CYCLINS; GENES, P53; HUMANS; LINEAR MODELS; MUTATION; NEOPLASMS; PROTEOMICS; RAS PROTEINS;

EID: 44449122938     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.4.895     Document Type: Article

References (39)

1. Funkhouser J: Reinventing pharma: the theranostic revolution. Cuff Drug Discov 2: 17-19, 2002.
2. Evans W and Relling V: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491, 1999.
3. Tanaka T, Tanimoto K, Otani K, et al: Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer 111: 617-626, 2004.
4. Shipp M, Ross K, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning, Nat Med 8: 68-74, 2002.
5. Clarke P, Te Poele R, Wooster RA and Workman P: Gene expression microarray analysis in cancer biology, pharmacology and drug development: progress and potential. Biochem Pharmacol 62: 1311-1336, 2001.
6. Van't Veer L and De Jong D: The microarray way to tailored cancer treatment. Nat Med 8: 13-14, 2002.
7. Jain R: Delivery of novel therapeutic agents in tumours: physiological barriers and strategies. J Natl Cancer Inst 81: 570-576, 1989.
8. Fertil B and Malaise E: Inherent cellular radiosensitivity as a basic concept for human tumour radiotherapy. Int J Radiat Oncol Biol Phys 7: 621-629, 1981.
9. Deacon J, Peckham M and Steel G: The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol 2: 317-333, 1984.
10. Warenius H, Britten R and Peacock J: The relative cellular radio sensitivity of 30 human in vitro cell lines of different histological type to high LET 62.5 MeV (p-->Be+) fast neutrons and 4 MeV photons. Radiother Oncol 30: 83-89, 1994.
11. O'Connor P, Jackman J, Bae I, et al: Characterisation of the p53 tumour suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4295-4300, 1997.
12. Mellish K and Kelland L and Harrap K: In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to CDDP. Br J Cancer 68: 240-250, 1993.
13. Britten R and Warenius H: De novo CDDP resistance does not influence cellular radio sens itiv ity. Eur J Cancer 29A: 1315-1320, 1993.
14. Warenius H, Seabra L and Maw P: Sensitivity to cisdiamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. Int J Cancer 67: 224-231, 1996.
15. Bilran H Jr, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, Bollig A, Sarkar F and Liao J: Overexpression of cyclin D1 promotes tumour cell growth and confers resistance to CDDP-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumour cell line. Clin Cancer Res 16: 6075-6086, 2005.
16. Kornmann M, Arber N and Korc M: Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to CDDP. J Clin Invest 101: 344-352, 1998.
17. Wang M, Yip H and Srivatsan E: Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to CDDP. Laryngoscope 111: 982-989, 2001.
18. Shuai X, Han G, Wang G and Chen J: Cyclin D1 antisense oligodeoxynucleotide inhibits growth and enhances chemosensitivity in gastric carcinoma cells. World J Gastroenterol 12: 1766-1769, 2006.
19. Zhang L, Plon S, Nuchtern J, Burlingame S, Blaney S, Rousseau R and Berg S: Cyclin D and CDDP toxicity in primary neuroblastoma cell lines. Anticancer Drugs 15: 883-888, 2004.
20. Dempke W, Voigt W, Grothey A, Hill B and Schmoll H-J: Cisplatin and oncogenes: a review. Anticancer Drugs 11: 225-236, 2000.
21. Pestell K, Hobbs S, Titley J, Kelland L and Walton M: Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 57: 503-511, 2000.
22. Reles A, Wen H, Schmider A, et al: Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7: 2984-2997, 2001.
23. Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C and Hara N: Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 34: 1352-1357, 1998.
24. Kern M, Helmbach H, Artuc M, Karmann D, Jurgovsky K and Schadendorf D: Human melanoma cell lines selected in vitro displaying various levels of drug resistance against CDDP, fotemustin, vindesin or etoposide: modulation of proto-oncogene expression. Anticancer Res 17: 43 59-4370, 1997.
25. Chui C, Lin C and Fang K: Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis. Apoptosis 10: 643-650, 2005.
26. Ravizza R, Garibioldi M, Passarelli L and Monti E: Role of p53/p21 system in the response of human colon carcinoma cells to doxorubicin. BMC Cancer 4: 92-102, 2004.
27. Munoz-Gamez J, Martin-Oliva D, Aguilar-Quesada R, Canuelo A, Nunez M, Valenzuela M, Ruiz de Almodovar J, De Murcia G and Oliver F: PARP inhibition senzitises p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 386: 119-125, 2005.
28. Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G and Zunino F: A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer 92: 738-747, 2001.
29. Lavarino C, Pilotti S, Oggionni M, et al: p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 19: 3936-3945, 2000.
30. Györffy B, Surowiak P, Kiesslich O, Denkert C, Schäfer R, Dietel M and Lage H: Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699-1712, 2006.
31. Warenius HM, Jones M, Gorman T, McLeish R, Seabra, L, Barraclough R and Rudland R: Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity. Br J Cancer 83: 1084-1095, 2000.
32. Kim A, Zhu Y, Han L, Kopelovitch L, Bickers D and Athar M: Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1 signalling pathways. Exp Dermatol 15: 538-546, 2006.
33. Hermann R, Fest J, Christiansen H, Hille A, Rave-Frank M, Nitsche M, Grundker C, Vierek V, Jarry H and Schmidtberger H: Radiosenzitisation dependent on p53 function in bronchial carcinoma cells by the isoflavogenistein and estradiol in vitro. Strahlenther Onkol 183: 195-200, 2007.
34. Lux X, Errington J, Curtin N, Lunec J and Newell D: The impact of p53 status on cellular sensitivity to antifolate drugs. J Clin Cancer Res 7: 2114-2123, 2001.
35. Yamashita T, Tokino T, Tanoki H, Moriuchi T, Jin H-Y, Omari F and Jimbow K: Induction of apoptosis in melanoma lines by p53 and its related proteins. J Invest Dermatol 117: 914-919, 2001.
36. Juang S, Pan W, Kuo C, Liou J, Hung Y, Chen L, Hsieh H and Chang J: A novel bis-benzylidenecyclopentanone derivative BPROY007, inducing a rapid caspase activation involving up-regulation of Fas (CD95/APO-1) and wild-type p53 in human epidermoid carcinoma cells. Biochem Pharmacol 68: 293-303, 2004.
37. Seabra L and Warenius H: Proteomic co-expression of cyclin-dependent kinases 1 and 4 in human cancer cells. Eur J Cancer 43: 1483-1492, 2007.
38. Doi T, Morita T, Wakabayashi N, Sumi T, Iwai S, Amekawe S, Sakuda M and Nishimune Y: Induction of instability of p34 (cdc2) expression by treatment with cisplatin (CDDP) in mouse teratocarcinoma F9 cells. Cancer Lett 176: 75-80, 2002.
39. King T, Akerlay W, Fan A, Moore T, Mangray S, Chen M and Safran H: P53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma. Cancer 89: 769-773, 2000.